

# CITATION REPORT

List of articles citing

## Repurposed Tocilizumab in Patients with Severe COVID-19

DOI: 10.4049/jimmunol.2000981

Journal of Immunology, 2021, 206, 599-606.

**Source:** <https://exaly.com/paper-pdf/77920413/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
15	Tocilizumab and mortality in hospitalised patients with covid-19. A systematic review comparing randomised trials with observational studies.		0
14	Efficacy and Safety of Tocilizumab Treatment COVID-19 Patients: A Case-Control Study and Meta-Analysis. <i>Infectious Diseases and Therapy</i> , <b>2021</b> , 10, 1677-1698	6.2	0
13	Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update. <i>Clinical Microbiology and Infection</i> , <b>2021</b> , 27, 1076-1082	9.5	14
12	Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: A systematic review and meta-analysis. <i>Reviews in Medical Virology</i> , <b>2021</b> , e2295	11.7	9
11	Beneficial and harmful outcomes of tocilizumab in severe COVID-19: A systematic review and meta-analysis. <i>Pharmacotherapy</i> , <b>2021</b> , 41, 884-906	5.8	7
10	Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis. <i>Respirology</i> , <b>2021</b> , 26, 1027-1040	3.6	7
9	Intensive Care Patients from the First COVID-19 Wave: One-Year Survival after Tocilizumab Treatment. <i>Journal of Personalized Medicine</i> , <b>2021</b> , 11,	3.6	1
8	Comparing the efficacy of tocilizumab with corticosteroid therapy in treating COVID-19 patients: a systematic review and meta-analysis.. <i>DARU, Journal of Pharmaceutical Sciences</i> , <b>2022</b> , 1	3.9	2
7	Association between tocilizumab treatment and clinical outcomes of COVID-19 patients: a systematic review and meta-analysis.. <i>Aging</i> , <b>2022</b> , 14,	5.6	0
6	Potential plants for inflammatory dysfunction in the SARS-CoV-2 infection.. <i>Inflammopharmacology</i> , <b>2022</b> , 1	5.1	
5	Complement C5a and Clinical Markers as Predictors of COVID-19 Disease Severity and Mortality in a Multi-Ethnic Population.. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 707159	8.4	2
4	Tocilizumab as a Treatment for Cytokine Storm in COVID-19 Patients: A systematic review. <b>2022</b> , 6,		
3	CD8+ T <sub>H</sub> 1-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. <b>2023</b> , 4, 100878		0
2	Highlights on molecular targets in the management of COVID-19: Possible role of pharmacogenomics. <b>2023</b> , 51, 030006052311537		0
1	Severe COVID-19: Drugs and Clinical Trials. <b>2023</b> , 12, 2893		0